NUTRIBAND INC (NTRB)

Company Profile

Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. The company is headquartered in Orlando, Florida. The company went IPO on 2017-06-20. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. The firm's development pipeline includes AVERSA Buprenorphine and AVERSA Methylphenidate. The firm is also developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. Its AVERSA Fentanyl is an abuse-deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse-deterrent technology to reduce the abuse and misuse of fentanyl patches. The company is also exploring transdermal delivery of proteins and peptides such as exenatide for type 2 diabetes and follicle-stimulating hormone (FSH) for infertility.

Company Info

NUTRIBAND INC

121 S Orange Ave Ste 1500

Orlando FLORIDA

P: 14073776695

CEO: Gareth Sheridan

Employees: 13

Website: https://nutriband.com/